Bladder carcinoma is the most common malignancy of the urinary tract. Approximately 75–
85% of patients with bladder cancer present with a disease that is confined to the mucosa …

Non-muscle invasive bladder cancer (NMIBC) is a heterogeneous population of tumours
accounting for 80% of bladder cancers. Over the years, the management of this disease has …

Purpose: Although associated with an overall favorable survival rate, the heterogeneity of
non-muscle invasive bladder cancer (NMIBC) affects patients' rates of recurrence and …

Aim This review article summarizes the current clinical practice guidelines around disease
definitions and risk stratifications, and the treatment of non-muscle-invasive bladder cancer …

CONTEXT: This review focuses on the prediction of recurrence and progression in non–
muscle invasive bladder cancer (NMIBC) and the treatments advocated for this disease …

Non—muscle-invasive bladder cancer (NMIBC) is a heterogeneous subclassification of
urothelial carcinoma with significant variation in individual risk of recurrence and …

CONTEXT: Although the European Association of Urology (EAU), First International
Consultation on Bladder Tumors (FICBT), National Comprehensive Cancer Network …

Abstract Context The European Association of Urology (EAU) has released an updated
version of the guidelines on non–muscle-invasive bladder cancer (NMIBC). Objective To …

Non-muscle-invasive bladder cancer (NMIBC) is an early-stage cancer without invasion into
the detrusor muscle layer. Transurethral resection of bladder tumour (TURBT) is a diagnostic …

CONTEXT: Understanding the epidemiology and risk factors for non–muscle invasive
bladder cancer (NMIBC) can assist in the prevention and early detection of the disease …